PharmAthene (PIP)

Add to Watchlists Create an Alert
1.61 -0.01  -0.62%   AMEX May 24, 3:30PM BATS Real time Currency in USD

PharmAthene R&D Expense Quarterly:

4.747M for Dec. 31, 2012
View Full Chart

PharmAthene R&D Expense Quarterly Chart

    PharmAthene Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 4.747M
    Sept. 30, 2012 5.139M
    June 30, 2012 4.919M
    March 31, 2012 4.705M
    Dec. 31, 2011 4.531M
    Sept. 30, 2011 4.884M
    June 30, 2011 5.984M
    March 31, 2011 5.820M
    Dec. 31, 2010 3.811M
    Sept. 30, 2010 6.172M
    June 30, 2010 5.940M
    March 31, 2010 4.952M
    Dec. 31, 2009 6.291M
       
    Sept. 30, 2009 7.884M
    June 30, 2009 10.23M
    March 31, 2009 5.695M
    Dec. 31, 2008 5.337M
    Sept. 30, 2008 9.414M
    June 30, 2008 11.18M
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    PIP R&D Expense Quarterly Benchmarks

    Companies
    Emergent BioSolutions 30.72M
    BioTime 4.793M
    Savient Pharmaceuticals 5.491M

    PIP R&D Expense Quarterly Rankings

    Overall 89th percentile
    854 of 8009
    Sector 64th percentile
    244 of 687 in Healthcare
    Industry 55th percentile
    111 of 248 in Biotechnology

    PIP R&D Expense Quarterly Range, Past 5 Years

    Minimum 3.811M Dec 2010
    Maximum 11.18M Jun 2008
    Average 6.191M